ProMIS Neurosciences发布新的同行评审论文,显示血浆Ptau作为阿尔茨海默症试验中的早期预测终点,支持其正在进行的Phase 1B Precise-Ad试验与Pmn310

美股速递
Dec 01, 2025

ProMIS Neurosciences发布新的同行评审论文,显示血浆Ptau作为阿尔茨海默症试验中的早期预测终点,支持其正在进行的Phase 1B Precise-Ad试验与Pmn310。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10